ATYPICAL ANTIPSYCHOTIC COMPLIANCE AND PERSISTENCE AND ASSOCIATED HEALTH CARE UTILIZATION IN THE TREATMENT OF SCHIZOPHRENIA
Author(s)
Shawn X Sun, PhD, Manager Health Outcomes Collaborative Research1, Gordon G Liu, PhD, Associate Professor2, Zhongyun Zhao, PhD, Health Outcomes Scientist31Walgreens Health Services, Deerfield, IL, USA; 2 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 3 Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To determine the compliance and persistence to atypical antipsychotics in the treatment of schizophrenia patients and associated health care utilization. METHODS: The study sample was based on NC Medicaid claims database. Patients were included if they had a diagnosis of schizophrenia (ICD-9 295.xx), received at least two antipsychotic prescriptions during the period after index date and were continuously enrolled in NC Medicaid Program during three month prior and one year post treatment periods. Medication possession ratio (MPR), persistence and medication use gap were used as compliance measures. Both descriptive and multivariate model were conducted. RESULTS: A total of 450 patients were included. Mean age was 42.3 years. 52.4% were men and 33.1% were blacks. Adherent (0.8
Conference/Value in Health Info
2006-05, ISPOR 2006, Philadelphia, PA
Value in Health, Vol. 9, No.3 (May/June 2006)
Code
PMH40
Topic
Patient-Centered Research
Topic Subcategory
Adherence, Persistence, & Compliance
Disease
Mental Health